Beijing Biostar Pharms Co Ltd (2563) Fair Value & Analysis

Healthcare · HK · Market cap HK$1.4B

Below-average quality, and screening another 59% overvalued on our models.

What matters now

• The price sits above even our optimistic bull case (HK$1.72). The favourable scenario is already priced in.
• The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
• Solid but not exceptional quality (45/100) and above fair value, neither a clear bargain nor a standout compounder.
• A fairly wide model range (HK$0.9100 to HK$1.72) leaves room in how you read the outcome.

Price vs Fair Value (21 months)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

21‑month range HK$2.63 – HK$35.45 · fair‑value band HK$0.9100 – HK$1.72 · the HK$3.38 price screens above the HK$1.38 fair value. Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Beijing Biostar Pharms Co Ltd (2563) currently trades at HK$3.38, while our model-based Fair Value estimate is HK$1.38, implying the stock looks roughly 59.1% overvalued today. The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).

Trailing-twelve-month revenue stands at HK$33.4M. Revenue declined 52.1% year over year. It earns a return on equity of -18.0%. The balance sheet holds a net cash position of HK$506M. Fundamentals as of Aug 13, 2026

Our scenario range runs from HK$0.9100 (bear case) to HK$1.72 (bull case); at HK$3.38, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 68% below its 52-week high and 41% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -47% fair-value upside, at -59%, 2563 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Key figures & financial health

Quality Score breakdown

About the company

Beijing Biostar Pharmaceuticals Co., Ltd., a synthetic biology-driven biopharmaceutical company, engages in the development, manufacturing, and commercialization of oncology products in the People's Republic of China.

Full company description

Beijing Biostar Pharmaceuticals Co., Ltd., a synthetic biology-driven biopharmaceutical company, engages in the development, manufacturing, and commercialization of oncology products in the People's Republic of China. The company develops Utidelone injections for metastatic breast cancer, breast cancer neoadjuvant, non-small cell lung cancer, pancreatic cancer, non-small cell lung cancer brain metastasis, and breast cancer brain metastasis indications; and Utidelone capsules for metastasis breast cancer, triple-negative breast cancer adjuvant intensive, first line gastric cancer, platinum-resistant ovarian cancer, and soft tissue sarcoma indications. It is also involved in the development of Utidelone antibody drug conjugate in preclinical studies; and BG22, BG18, and BG44 products for solid tumor indications in preclinical studies. Beijing Biostar Pharmaceuticals Co., Ltd. was incorporated in 2002 and is headquartered in Beijing, China.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Beijing Biostar Pharms Co Ltd reported revenue of HK$37.1M in FY2025 versus HK$107M in FY2021, a compound −23.2%/yr. Reported net income was −HK$143M in FY2025.

2563 screens 59% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Peer Group

Biotechnology · 605 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Biotechnology median · lower = cheaper

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.